Influenza: treatment and prevention

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Influenza affects 10–20 per cent of the global population. The influenza virus belongs to the orthomyxovirus family. It is made up of a lipid membrane surrounding a protein shell and a core containing eight RNA segments. There are three types of influenza virus (A, B and C), based on the protein composition of the viral envelope. Annual flu epidemics are caused by types A or B, with the type B being identified as dominant last year (75 per cent of flu infections in the UK were caused by influenza B). Influenza B usually causes minor symptoms but infection can be severe for older people. Influenza viruses can be further categorised according to the classes of surface proteins they express. Subtypes of influenza A are differentiated by the variability of their surface glycoproteins (haemagglutinin [H] and neuraminidase [N]). There are 16 types of haemagglutinin and nine types of neur-aminidase. These antigenic variants are named according to their H and N antigen types. The main subtypes known to cause influenza are H1N1, H2N2 and H3N2. All influenza viruses undergo mutation. Point mutations occur in the amino acid sequences of the haemagglutinin and neuraminidase glycoproteins and this results in slight modifications (antigenic drift) in the virus, allowing for the development of new strains within a subtype. Viral strains are named according to the virus type, geographical origin, strain number, year of isolation and subtype.
Original languageEnglish
Pages (from-to)399-402
Number of pages4
JournalPharmaceutical Journal
Volume277
Issue number7420
Publication statusPublished - 1 Sep 2006

Fingerprint

Human Influenza
Orthomyxoviridae
Hemagglutinins
Influenzavirus C
HN Protein
Viral Envelope Proteins
Viruses
Influenza B virus
Membrane Glycoproteins
Influenza A virus
Neuraminidase
Membrane Lipids
Infection
Point Mutation
Amino Acid Sequence
Membrane Proteins
RNA
Mutation
Population
Proteins

Keywords

  • influenza
  • vaccine
  • drug development

Cite this

Perrie, Yvonne. / Influenza : treatment and prevention. In: Pharmaceutical Journal. 2006 ; Vol. 277, No. 7420. pp. 399-402.
@article{054141de77d845e1882e71673e28ef61,
title = "Influenza: treatment and prevention",
abstract = "Influenza affects 10–20 per cent of the global population. The influenza virus belongs to the orthomyxovirus family. It is made up of a lipid membrane surrounding a protein shell and a core containing eight RNA segments. There are three types of influenza virus (A, B and C), based on the protein composition of the viral envelope. Annual flu epidemics are caused by types A or B, with the type B being identified as dominant last year (75 per cent of flu infections in the UK were caused by influenza B). Influenza B usually causes minor symptoms but infection can be severe for older people. Influenza viruses can be further categorised according to the classes of surface proteins they express. Subtypes of influenza A are differentiated by the variability of their surface glycoproteins (haemagglutinin [H] and neuraminidase [N]). There are 16 types of haemagglutinin and nine types of neur-aminidase. These antigenic variants are named according to their H and N antigen types. The main subtypes known to cause influenza are H1N1, H2N2 and H3N2. All influenza viruses undergo mutation. Point mutations occur in the amino acid sequences of the haemagglutinin and neuraminidase glycoproteins and this results in slight modifications (antigenic drift) in the virus, allowing for the development of new strains within a subtype. Viral strains are named according to the virus type, geographical origin, strain number, year of isolation and subtype.",
keywords = "influenza, vaccine, drug development",
author = "Yvonne Perrie",
year = "2006",
month = "9",
day = "1",
language = "English",
volume = "277",
pages = "399--402",
journal = "Pharmaceutical Journal",
issn = "0031-6873",
number = "7420",

}

Perrie, Y 2006, 'Influenza: treatment and prevention', Pharmaceutical Journal, vol. 277, no. 7420, pp. 399-402.

Influenza : treatment and prevention. / Perrie, Yvonne.

In: Pharmaceutical Journal, Vol. 277, No. 7420, 01.09.2006, p. 399-402.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Influenza

T2 - treatment and prevention

AU - Perrie, Yvonne

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Influenza affects 10–20 per cent of the global population. The influenza virus belongs to the orthomyxovirus family. It is made up of a lipid membrane surrounding a protein shell and a core containing eight RNA segments. There are three types of influenza virus (A, B and C), based on the protein composition of the viral envelope. Annual flu epidemics are caused by types A or B, with the type B being identified as dominant last year (75 per cent of flu infections in the UK were caused by influenza B). Influenza B usually causes minor symptoms but infection can be severe for older people. Influenza viruses can be further categorised according to the classes of surface proteins they express. Subtypes of influenza A are differentiated by the variability of their surface glycoproteins (haemagglutinin [H] and neuraminidase [N]). There are 16 types of haemagglutinin and nine types of neur-aminidase. These antigenic variants are named according to their H and N antigen types. The main subtypes known to cause influenza are H1N1, H2N2 and H3N2. All influenza viruses undergo mutation. Point mutations occur in the amino acid sequences of the haemagglutinin and neuraminidase glycoproteins and this results in slight modifications (antigenic drift) in the virus, allowing for the development of new strains within a subtype. Viral strains are named according to the virus type, geographical origin, strain number, year of isolation and subtype.

AB - Influenza affects 10–20 per cent of the global population. The influenza virus belongs to the orthomyxovirus family. It is made up of a lipid membrane surrounding a protein shell and a core containing eight RNA segments. There are three types of influenza virus (A, B and C), based on the protein composition of the viral envelope. Annual flu epidemics are caused by types A or B, with the type B being identified as dominant last year (75 per cent of flu infections in the UK were caused by influenza B). Influenza B usually causes minor symptoms but infection can be severe for older people. Influenza viruses can be further categorised according to the classes of surface proteins they express. Subtypes of influenza A are differentiated by the variability of their surface glycoproteins (haemagglutinin [H] and neuraminidase [N]). There are 16 types of haemagglutinin and nine types of neur-aminidase. These antigenic variants are named according to their H and N antigen types. The main subtypes known to cause influenza are H1N1, H2N2 and H3N2. All influenza viruses undergo mutation. Point mutations occur in the amino acid sequences of the haemagglutinin and neuraminidase glycoproteins and this results in slight modifications (antigenic drift) in the virus, allowing for the development of new strains within a subtype. Viral strains are named according to the virus type, geographical origin, strain number, year of isolation and subtype.

KW - influenza

KW - vaccine

KW - drug development

UR - http://www.pharmaceutical-journal.com/learning/learning-article/influenza-treatment-and-prevention/10002226.article

M3 - Article

VL - 277

SP - 399

EP - 402

JO - Pharmaceutical Journal

JF - Pharmaceutical Journal

SN - 0031-6873

IS - 7420

ER -